Roivant reports Phase 2 win for lung disease drug that it got from Bayer

Roivant's Pulmovant reports positive mosliciguat Phase 2 data in PH-ILD, topping Wall Street's bar for Phase 3 advancement.

Raccontata daendpoints.news